{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1032.61","meta":{"versionId":"9","lastUpdated":"2018-05-09T01:07:38.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"MITRE Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2018-05-09"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.61","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1032.61"}],"version":"20180509","name":"Immunotherapy","title":"Immunotherapy","status":"active","experimental":false,"date":"2018-05-09T01:00:04-04:00","publisher":"MITRE Steward","description":"THIS VALUE SET IS UNDERGOING TESTING. PLEASE USE CAUTION IF CONSIDERING USE OF THIS VALUE SET.","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: Immunotherapy procedures that might be used to treat cancer. THIS VALUE SET IS UNDERGOING TESTING. PLEASE USE CAUTION IF CONSIDERING USE OF THIS VALUE SET.),(Data Element Scope: Immunotherapy procedures represented by ICD10PCS codes. THIS VALUE SET IS UNDERGOING TESTING. PLEASE USE CAUTION IF CONSIDERING USE OF THIS VALUE SET.),(Inclusion Criteria: Immunotherapy procedures. THIS VALUE SET IS UNDERGOING TESTING. PLEASE USE CAUTION IF CONSIDERING USE OF THIS VALUE SET.),(Exclusion Criteria: Non-immunotherapy procedures used to treat cancer (e.g., chemotherapy). THIS VALUE SET IS UNDERGOING TESTING. PLEASE USE CAUTION IF CONSIDERING USE OF THIS VALUE SET.)","compose":{"include":[{"system":"http://www.cms.gov/Medicare/Coding/ICD10","concept":[{"code":"XW03351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW033C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3"},{"code":"XW04351","display":"Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1"},{"code":"XW043C3","display":"Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3"}]}]},"expansion":{"identifier":"urn:uuid:909cb380-5dd3-4fb1-97c4-1b28ed8ce6fe","timestamp":"2023-12-10T20:42:55-05:00","total":0}}